{
    "relation": [
        [
            "",
            "DTG 10 mg OD",
            "DTG 25 mg OD",
            "DTG 50 mg OD",
            "EFV 600 mg OD"
        ],
        [
            "Description",
            "Participants received DTG 10 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally OD for 96 weeks. Following Week 96, participants continued to receive DTG 50 mg OD.",
            "Participants received DTG 25 mg, DTG matching placebo, and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally OD for 96 weeks. Following Week 96, participants continued to receive DTG 50 mg OD.",
            "Participants received DTG 50 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally OD for 96 weeks. Following Week 96, participants continued to receive DTG 50 mg OD.",
            "Participants received Efavirenz (EFV) 600 mg and ABC/3TC 600 mg/300 mg or TDF/FTC 300 mg/200 mg orally OD for 96 weeks."
        ]
    ],
    "pageTitle": "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00951015?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988048.90/warc/CC-MAIN-20150728002308-00059-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 855745437,
    "recordOffset": 855729043,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Eligible participants (par.) were randomized (ran) to receive Dolutegravir (DTG) (3 dose groups) or Efavirenz for 96 weeks. At Week 96, par. ran. to any dose of DTG entered an open-label phase and continued to receive DTG at the selected dose of 50 milligrams. A total of 208 par. were ran., and 205 received at least one dose of study medication. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: GSK1349572 Drug: efavirenz Interventions: Infection, Human Immunodeficiency Virus Condition:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 DTG 10 mg OD \u00a0 \u00a0 DTG 25 mg OD \u00a0 \u00a0 DTG 50 mg OD \u00a0 \u00a0 EFV 600 mg OD \u00a0 STARTED \u00a0 \u00a0 53 \u00a0 \u00a0 51 \u00a0 \u00a0 51 \u00a0 \u00a0 50 \u00a0 Ongoing \u00a0 \u00a0 47 \u00a0 \u00a0 45 \u00a0 \u00a0 46 \u00a0 \u00a0 8 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 32 \u00a0 NOT COMPLETED \u00a0 \u00a0 53 \u00a0 \u00a0 51 \u00a0 \u00a0 51",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}